Study to Evaluate the Efficacy and Safety of Eribulin Mesylate in Combination With Pembrolizumab in Participants With Metastatic Triple-Negative Breast Cancer (mTNBC)
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Breast Neoplasm
Interventions: DRUG: Eribulin Mesylate|DRUG: Pembrolizumab
Sponsor: Eisai Inc.
Collaborators: Merck Sharp & Dohme LLC